A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

NCT07645287 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: GS-3242 Tablet
DRUG: GS-3242 Injection
DRUG: Lenacapavir Tablet
DRUG: Lenacapavir Injection
DRUG: B/F/TAF

Sponsor

Gilead Sciences